SREBF1 and hyperlipidemia: These data were also parallel to the degree of decreased hyperlipidemia and hepatic steatosis and improved liver function indices ALT and AST, suggesting that the AMPK/ACC/SREBP‐1c pathway likely participates in mediating the anti‐obesity and metabolic disorder improvement properties of alisol A.